期刊文献+

Ⅰ型肝肾综合征的临床分析 被引量:4

Clinical analysis of type I hepatorenal syndrome
下载PDF
导出
摘要 目的探讨Ⅰ型肝肾综合征的发病原因、诱因及临床指标变化,以提高对该病的整体认知水平。方法回顾性查阅我院2000年至今收治的Ⅰ型HRS住院患者病例29例,分析其基础疾病及病因;发生肝肾综合征的诱因;肝肾功能及凝血象变化;CTP及MELD肝功能分级;尿量变化及生存率等。结果Ⅰ型HRS主要发生于晚期肝硬化和重症肝炎患者。易出现腹水、肝性脑病、感染及消化道出血等并发症。Child-Pugh评分多在B级和C级,以C级为主(82.76%)。MELD评分中有27例在20分以上(93.1%),多数位于20~40分之间。Child-Pugh评分B级和C级间的MELD评分存在显著性差异。其尿量逐渐减少,甚至无尿。29例患者中21例在住院期间死亡,8例自动出院。结论Ⅰ型HRS患者死亡率极高,应争取早发现、早诊断、早治疗,以改善预后。 Objective To analyze the clinical feature of type Ⅰ hepatorenal syndrome (HRS). Methods We reviewed the clinical records of 29 type Ⅰ HRS patients who were diagnosed based on the International Ascites Club criteria. Serveral clinical factors of these patients were collected and analyzed to characterize the type Ⅰ HRS. Results Type Ⅰ HRS mainly occurred in the late cirrhosis and severe hepatitis patients. The patients of type Ⅰ HRS tended to appear ascites, hepatic encephalopathy, infection and gastroenterology bleeding. Child-Pugh scores were always in the B and C level, mainly C level (82.76%). There had 27 cases (93.1%) whose MELD score was more than 20 points, mainly in 20 -40 points. There was a significant difference of MELD score between Child-Pugh B and C level. Urine of these patients gradually reduced, even anuria. Twenty-one patients were dead during hospitalization and eight patients were discharged by themselves. Conclusion The mortality of type Ⅰ HRS is very high. So these patients should be early found, early diagnosis, early treatment to improve the prognosis.
出处 《胃肠病学和肝病学杂志》 CAS 2009年第3期231-232,共2页 Chinese Journal of Gastroenterology and Hepatology
基金 重庆市科委自然科学基金(CSCT2005BB5311)
关键词 肝肾综合征 肝功能衰竭 肝硬化 Hepatorenal syndrome Liver function failure Liver cirrhosis
  • 相关文献

参考文献7

  • 1Arroyo V, Gines P, Gerbes AL, et al. Definition and diagnostic criteria of refractory ascites and hepatorenalsyndrome in cirrhosis [ J]. Hepatology, 1996, 23( 1 ) : 164-176.
  • 2Salerno F, Gerbes A, Gin,s P, at al. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis: a consensus workshop of the international ascites club [J]. Gut, 2007, 56(9): 1310-1318.
  • 3中华医学会传染病与,寄生虫病学分会,肝病学分会.病毒性肝炎防治方案[J].中华肝脏病杂志,2000,8(6):324-329. 被引量:14014
  • 4张洪球.Lipo PGE_1治疗肝肾综合征的疗效观察[J].胃肠病学和肝病学杂志,2004,13(2):193-194. 被引量:6
  • 5Forman LM, Lucey MR. Predicting the prognosis of chronic liver disease: an evolution from Child to MELD [J]. Hepatology, 2001, 33 (2) : 473-475.
  • 6Kamath PS, Wiesner RH, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease [ J ]. Hepatology, 2001, 33(2) : 464-470.
  • 7宋春辉,陈黎明,张玲霞.409例肝硬化和重型肝炎病例的MELD评分结果的构成分析[J].中华实验和临床病毒学杂志,2007,21(2):168-170. 被引量:6

二级参考文献3

  • 1张玲霞,王永怡.急性肝衰竭预后的判断.顾长海,王永明,主编.急性肝衰竭[M].成都:四川科学技术出版社,1997.314.
  • 2Forman LM, Lucey MR. Predicting the prognosis of chronic liver disease: an evolution from the Child to MELD. Hepatology, 2001, 33 : 473-475.
  • 3中华医学会传染病与,寄生虫病学分会,肝病学分会.病毒性肝炎防治方案[J].中华肝脏病杂志,2000,8(6):324-329. 被引量:14014

共引文献14022

同被引文献38

  • 1王静艳,刘沛.肝肾综合征的发病机制的研究进展[J].世界华人消化杂志,2004,12(11):2668-2670. 被引量:6
  • 2Salerno F, Gerbes A, Gines P, et al. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis [ J]. Gut, 2007, 56 (9) : 1310-1318.
  • 3Gines P, Guevara M, Arroyo V, et al. Hepatorenal syndrome [ J]. Lancet, 2003, 362(9398): 1819-1827.
  • 4Kiser TH, Maclaren R, Fish DN. Treatment of hepatorenal syndrome [J]. Pharmacotherapy, 2009, 29(10): 1196-1211.
  • 5Stadlbauer V, Wright GA, Banaji M, et al. Relationship between activation of the sympathetic nervous system and renal blood flow autoregulation in cirrhosis [J]. Gastroenterology, 2008, 134(1) : 111-119.
  • 6Ruizdel-Arbol L, Monescillo A, Arocena C, et al. Circulatory function and hepatorenal syndrome in cirrhosis [J] . Hepatology, 2005, 42 (2) : 439-447.
  • 7Moreau R, Lebrec D. Diagnosis and treatment of acute renal failure in patients with cirrhosis [ J]. Best Pract Res Clin Gastroenterol, 2007, 21(1): 111-123.
  • 8Fabrizi F, Dixit V, Messa P, et al. Terlipressin for hepatorenal syndrome: A meta-analysis of randomized trials [J]. Int J Artif Organs, 2009, 32(3): 133-140.
  • 9Sanyal A J, Boyer T, Gareia-Tsao G, et al. A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome [ J ]. Gastroenterology, 2008, 134 ( 5 ) : 1360-1368.
  • 10Slack AJ, Wendon J, The liver and kidney in critically ill patients[J]. Blood Purif, 2009, 28(2) : 124-134.

引证文献4

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部